ReviewClinical microbiology reviews2012
Colonization by Pneumocystis jirovecii and its role in disease.
Review in Clinical microbiology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02669706 (Assessment of the Safety and Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia in Patients With Hematologic Malignancies and Stem Cell Transplant Recipients.), which is not on this map. Cited by 207 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of the Safety and Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia in Patients With Hematologic Malignancies and Stem Cell Transplant Recipients.
Who cites it
207 citing papers in PubMed, 2 syntheses or guidelines pooled it, 422 citations in OpenAlex.
- Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.The Cochrane database of systematic reviews · 2014Pooled it
- Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.Annals of the rheumatic diseases · 2017Trial
- Article
- Pneumocystis jirovecii pneumonia and prophylaxis in patients with solid tumours: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Blood mNGS: an effective non-invasive diagnostic tool for Pneumocystis jirovecii pneumonia.BMC microbiology · 2026Article
- Evaluation of the ELITe InGenius PCR assay compared with immunofluorescence for Pneumocystis jirovecii detection in respiratory samples.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Extrapulmonary and OtherJournal of fungi (Basel, Switzerland) · 2026Article
- Past Achievements, Present Gaps, and Future Priorities in Pneumocystis jirovecii Research: A Global Bibliometric Analysis.Pathogens (Basel, Switzerland) · 2026Review
- Predicting antifolate resistance in the unculturable fungal pathogen Pneumocystis jirovecii.PLoS genetics · 2026Article
- A diagnostic model for discrimination between Pneumocystis jirovecii pneumonia and colonization based on multiple parameters.Scientific reports · 2026Article
- Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case reports.Immunologic research · 2026Article
- Strain-Dependent Protective Innate Immunity AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Biomarkers in Invasive Pulmonary Fungal Infections: Where Do We Stand?Journal of fungi (Basel, Switzerland) · 2026Review
- Immune Responses toJournal of inflammation research · 2026Review
- Blood mNGS-Detected Epstein-Barr Virus in ICU Patients with Pneumonia: Associations with Disease Severity Markers and Inflammatory Burden.Infection and drug resistance · 2026Article
- Advances in pathogen detection ofInfectious medicine · 2025Review
- Development of a vaccine construct againstNAR genomics and bioinformatics · 2025Article
- Article
- Significant Mortality Reduction from SeverePathogens (Basel, Switzerland) · 2025Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the introduction of combination antiretroviral therapy, it remains an important cause of disease in both HIV-infected and non-HIV-infected immunosuppressed populations. The epidemiology of PCP has shifted over the course of the HIV epidemic both from changes in HIV and PCP treatment and prevention and from changes in critical care medicine. Although less common in non-HIV-infected immunosuppressed patients, PCP is now more frequently seen due to the increasing numbers of organ transplants and development of novel immunotherapies. New diagnostic and treatment modalities are under investigation. The immune response is critical in preventing this disease but also results in lung damage, and future work may offer potential areas for vaccine development or immunomodulatory therapy. Colonization with Pneumocystis is an area of increasing clinical and research interest and may be important in development of lung diseases such as chronic obstructive pulmonary disease. In this review, we discuss current clinical and research topics in the study of Pneumocystis and highlight areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.